The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
Open accessAbstract
Purpose: To evaluate whether capecitabine plus oxaliplatin (XELOX) is noninferior to fluorouracil. folinic acid, and oxaliplatin (FOLFOX-4) as first-line therapy in metastatic colorectal cancer (MCRC). Patients and Methods: The initial design of this trial was a randomized, two-arm, noninferiority, phase III comparison of XELOX versus FOLFOX-4. After patient accrual had begun, the trial design was amended in 2003 after bevacizumab phase III data became available. The resulting 2 × 2 factorial design randomly assigned patients to XELOX versus FOLFOX-4, and then to also receive either bevacizumab or placebo. We report here the results of the analysis of the XELOX versus FOLFOX-4 arms. The analysis of bevacizumab versus placebo with oxaliplatin-based chemotherapy is reported separately. The prespecified primary end point for the noninferiority analysis was progression-free survival. Results: The intent-to-treat population comprised 634 patients from the original two-arm portion of the study, plus an additional 1,400 patients after the start of the amended 2 × 2 design, for a total of 2,034 patients. The median PFS was 8.0 months in the pooled XELOX-containing arms versus 8.5 months in the FOLFOX-4–containing arms (hazard ratio [HR], 1.04; 97.5% CI, 0.93 to 1.16). The median overall survival was 19.8 months with XELOX versus 19.6 months with FOLFOX-4 (HR, 0.99; 97.5% CI, 0.88 to 1.12). FOLFOX-4 was associated with more grade 3/4 neutropenia/granulocytopenia and febrile neutropenia than XELOX, and XELOX with more grade 3 diarrhea and grade 3 hand-foot syndrome than FOLFOX-4. Conclusion: XELOX is noninferior to FOLFOX-4 as a first-line treatment for MCRC, and may be considered as a routine treatment option for appropriate patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citationSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Self-citationCapecitabine as Adjuvant Treatment for Stage III Colon Cancer
Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043116 · Cited by 1,248
Self-citationHoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Self-citationVan Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
Self-citationCassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.069 · Cited by 525
Self-citationCutsem, E. V., Hoff, P. M., Harper, P., Bukowski, R. M., Cunningham, D., Dufour, P., Graeven, U., Lokich, J., Madajewicz, S., Maroun, J. A., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601676 · Cited by 401
Porschen, R., Arkenau, H.-T., Kubicka, S., Greil, R., Seufferlein, T., Freier, W., Kretzschmar, A., Graeven, U., Grothey, A., Hinke, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2684 · Cited by 280
Cited by
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citationSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Self-citationJapanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialHashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,922
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Self-citationCunningham, D., Atkin, W., Lenz, H.-J., Lynch, H. T., Minsky, B., Nordlinger, B., & Starling, N. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60353-4 · Cited by 1,351
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y.-J., Cooper, H. S., Deming, D., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,330
Self-citationVan Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Noh, S. H., Park, S. R., Yang, H.-K., Chung, H. C., Chung, I.-J., Kim, S.-W., Kim, H.-H., Choi, J.-H., Kim, H.-K., Yu, W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70473-5 · Cited by 1,049
NCCN Guidelines Insights: Colon Cancer, Version 2.2018
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Engstrom, P. F., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0021 · Cited by 806
Self-citationHaller, D. G., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., Hill, M., Gilberg, F., Rittweger, K., & Schmoll, H.-J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.6297 · Cited by 784
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Itabashi, M., Shimada, Y., Tanaka, S., Ito, Y., Ajioka, Y., Hamaguchi, T., Hyodo, I., Igarashi, M., et al. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0315-2 · Cited by 700
Yoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T. W., Ismail, F., Tan, I. B., Yeh, K.-H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx738 · Cited by 573
Watanabe, T., Itabashi, M., Shimada, Y., Tanaka, S., Ito, Y., Ajioka, Y., Hamaguchi, T., Hyodo, I., Igarashi, M., Ishida, H., et al. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0801-z · Cited by 590
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Metastatic Colorectal Cancer: Current State and Future Directions
Fakih, M. G. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7633 · Cited by 527
Hofheinz, R.-D., Wenz, F., Post, S., Matzdorff, A., Laechelt, S., Hartmann, J. T., Müller, L., Link, H., Moehler, M., Kettner, E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70116-x · Cited by 509
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
Van Cutsem, E., Nordlinger, B., & Cervantes, A. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq222 · Cited by 479
Chibaudel, B., Maindrault-Goebel, F., Lledo, G., Mineur, L., André, T., Bennamoun, M., Mabro, M., Artru, P., Carola, E., Flesch, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4344 · Cited by 395
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H.-J., & Ladner, R. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.51 · Cited by 388
Colorectal cancer: From prevention to personalized medicine
Binefa, G. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i22.6786 · Cited by 382
Chua, Y. J., Barbachano, Y., Cunningham, D., Oates, J. R., Brown, G., Wotherspoon, A., Tait, D., Massey, A., Tebbutt, N. C., & Chau, I. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70381-x · Cited by 319
Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment
Burgess, J., Ferdousi, M., Gosal, D., Boon, C., Matsumoto, K., Marshall, A., Mak, T., Marshall, A., Frank, B., Malik, R. A., et al. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00168-y · Cited by 306
S3-Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008
Schmiegel, W., Reinacher-Schick, A., Arnold, D., Graeven, U., Heinemann, V, Porschen, R., Riemann, J., Rödel, C., Sauer, R., Wieser, M., et al. (2008) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2008-1027726 · Cited by 274
Okines, A. F. C., Norman, A. R., McCloud, P., Kang, Y.-K., & Cunningham, D. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp047 · Cited by 258
Hachey, S. J., Movsesyan, S., Nguyen, Q. H., Burton-Sojo, G., Tankazyan, A., Wu, J., Hoang, T., Zhao, D., Wang, S., Hatch, M. M., et al. (2021) · Lab on a Chip · doi:10.1039/d0lc01216e · Cited by 124
Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
Wortmann, S., Quinkler, M., Ritter, C., Kroiss, M., Johanssen, S., Hahner, S., Allolio, B., & Fassnacht, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0804 · Cited by 133
Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J. P., Gilberg, F., & Cunningham, D. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr031 · Cited by 90
Self-citationA Practical Approach to Fatigue Management in Colorectal Cancer
Aapro, M., Scotte, F., Bouillet, T., Currow, D., & Vigano, A. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.04.010 · Cited by 54
Weaver, A., Love, S. B., Larsen, M., Shanyinde, M., Waters, R., Grainger, L., Shearwood, V., Brooks, C., Gibson, O., Young, A. M., et al. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2224-1 · Cited by 30
Atreya, C. E., Yaeger, R., & Chu, E. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175679 · Cited by 35
Mizushima, T., Ide, Y., Murata, K., Ohashi, I., Yasumasa, K., Fukunaga, M., Takemoto, H., Tamagawa, H., Hasegawa, J., Hata, T., et al. (2013) · Oncology · doi:10.1159/000356018 · Cited by 8
Metadata
- Authors
- Cassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., Couture, F., Sirzén, F., & Saltz, L.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-04-20
- Volume
- 26
- Issue
- 12
- Pages
- 2006-2012
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2085705101
- Cited by
- 862
- References
- 14
- FWCI
- 34.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.